$CLDX News

Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup

Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $54

Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $48

Celldex Therapeutics Q1 EPS $(1.18) Beats $(1.20) Estimate, Sales $15.000K Miss $972.222K Estimate

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial

Barclays Upgrades Celldex Therapeutics to Overweight, Raises Price Target to $45

Celldex Therapeutics Files Prospectus To Offer 10,345,000 Shares Of Common Stock

Reported Earlier, Celldex Therapeutics Prices $300M Public Offering Of 10,345,000 Common Shares At $29.00 Per Share

Celldex Therapeutics shares are trading lower after the company announced an offering.

Celldex Therapeutics Commences Common Stock Offering; Terms Undisclosed

Celldex Presents Announces Data From Phase 2 Clinical Studies Of Barzolvolimab In Chronic Spontaneous Urticaria And Cold Urticaria And Symptomatic Dermographism Shows Enhancement In Patient Quality Life Throughout All Measures Domains

Goldman Sachs Maintains Neutral on Celldex Therapeutics, Raises Price Target to $34

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory

Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Celldex Presents Additional Results From Phase 2 Clinical Sturies Of Barzolvolimab In Chronic Spontaneous Urticaria And Cold Urticaria And Symptomatic Dermographism At 2026 Allergy, Asthma & Immunology's Annual Meeting

Celldex Therapeutics Stock Earns 88 RS Rating

Stifel Reiterates Buy on Celldex Therapeutics, Raises Price Target to $68

Celldex: Q4 Earnings Snapshot